BeBetter Medicine
1 known investors
Guangzhou-based developer of small molecule drugs for lymphoma, lung cancer, and ovarian cancer, including BEBT-908, a dual-target drug for recurrent or refractory lymphoma.
1 known investors
Guangzhou-based developer of small molecule drugs for lymphoma, lung cancer, and ovarian cancer, including BEBT-908, a dual-target drug for recurrent or refractory lymphoma.